Advances in Autologous Stem Cell Transplantation

References

• Autologous Blood and Marrow Transplant Registry Newsletter-. North America. 1995; Vol 2, No 1
   Google Scholar
• Peters W P, Fay J W, Holland H K, et al. Autologous bone marrow transplantation in primary breast cancer: The American experience. Bone Marrow Transplant 1995; 15(1)5254–5259
   Google Scholar
• Frei E, III. Creative cancer therapy. Cancer Res 1985; 45: 6523–6537
   PubMed Web of Science ®Google Scholar
• Devita V T, Serpick A, Calbone P. Combination chemotherapy of advanced hodgkin's disease. Ann Intern Med 1970; 73: 891
   Google Scholar
• Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–1288
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P. Dose response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10–15
   PubMed Web of Science ®Google Scholar
• Pinkel D, Hernandez K, Borella, et al. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 1971; 27: 247–256
   PubMed Web of Science ®Google Scholar
• Samson M K, Rivkin S E, Jones S E, et al. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer: A Southwest Oncology Group study. Cancer 1984; 53: 1029–1035
   PubMed Web of Science ®Google Scholar
• Shea T C, Mason J R, Storniolo A M, et al. Sequential cycles of high-dose carboplatin administered with recombinant human GM-CSF and repeated infusions of autologous peripheral blood progenitor cells; an effective method for delivering multiple courses of dose intensive therapy. J Clin Oncol 1992; 10(3)464–473
   PubMed Web of Science ®Google Scholar
• Shea T C, Mason J R, Breslin M, et al. Reinfusion and serial measurements of carboplatin-mobilized peripheral blood progenitor cells in patient receiving multiple cycles of high-dose chemotherapy. J Clin Oncol 1994; 12(5)1012–1020
   PubMed Web of Science ®Google Scholar
• Von Hoff D D, Clark G M, Weiss C R, et al. Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 1986; 4: 1827–1834
   PubMed Web of Science ®Google Scholar
• Livingston Robert B. High dose cancer therapy without stem cell support-Human solid tumors. High Dose Cancer Therapy Pharmacology, Hemopoietins, Stem Cells, J O Armitage, K H Antman. Williams & Wilkins, Philadelphia 1992; 195–210
   Google Scholar
• Socinski M A, Elias A, Schnipper L, et al. Granulocyte-macrophage colony-stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194–1198
   PubMed Web of Science ®Google Scholar
• Richman C M, Weiner R S, Yankee R A. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031–1039
   PubMed Web of Science ®Google Scholar
• To L B, Haylock D N, Thorp D, et al. The optimization of collection of peripheral blood stem cells for autotransplantation in acute myeloid leukemia. Bone Marrow Transplant 1989; 4: 41–47
   PubMed Web of Science ®Google Scholar
• Siena S, Bregni M, Brando B, et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony stimulating factor. Blood 1989; 74: 1905–1914
   PubMed Web of Science ®Google Scholar
• Ho A D, GlÜUuck S, Germond C, Sinoff C, Dietz G, Maruyama M, Corringham R ET. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. Leukemia 1993; 7: 1738–1746
   PubMed Web of Science ®Google Scholar
• Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81: 3158–3163
   PubMed Web of Science ®Google Scholar
• Burtness B, Henderson Bakas M, D'Andrea E. Single agent paclitaxel mobilizes CD34+ cells effectively. Proc ASCO 1995; 14: 108, abstract 131
   Google Scholar
• Sheridan W P, Begley C G, To L B, et al. Phase II study of autologous filgrastim (G-CSF) mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994; 14(1)105–111
   PubMed Web of Science ®Google Scholar
• Lane T A, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation. Blood 1995; 85: 275–282
   PubMed Web of Science ®Google Scholar
• Ho A D, Young D, Maruyama M, et al. Mobilization and purification of CD34+ cells from normal donors-Regimens with G-CSF, GM-CSF or a combination of both. Bone Marrow Transplant 1996; 7(2)S34–S37
   Google Scholar
• Gorin N C, Coiffier B, Hayat M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-hodgkin's lymphoma: A double-blind placebo-controlled trial. Blood 1992; 80(5)1149–1157
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Rosenfeld C S, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 949–954
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Singer J W. The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous and allogeneic bone marrow transplantation. Cancer Invest 1993; 11(2)224–228
   PubMed Web of Science ®Google Scholar
• Rabinowe S N, Neuberg D, Bierman P J, et al. Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood 1993; 81(7)1903–19098
   PubMed Web of Science ®Google Scholar
• Madero L, Munoz A, Diaz De Heredia A, et al. G-CSF after autologous bone marrow transplantation for malignant diseases in children. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplant 1995; 15(3)349–351
   PubMed Web of Science ®Google Scholar
• Link H, Boogaerts M A, Carella A M, et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992; 80(9)2188–2195
   PubMed Web of Science ®Google Scholar
• Wingo P A, Tong T, Bolden S. Cancer statistics 1995. CA Cancer Clin 1995; 45(1)8–30
   PubMed Web of Science ®Google Scholar
• Peters W P, Ross M, Vredenburgh J J, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high risk primary breast cancer. J Clin Oncol 1993; 11: 1132–1143
   PubMed Web of Science ®Google Scholar
• Antman K, Gale R P. Advanced breast cancer: High-dose chemotherapy and bone marrow auto transplants. Ann Intern Med 1988; 108: 570–574
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 70–85
   Google Scholar
• Henderson I C. Chemotherapy for metastatic disease. Breast Diseases, J R Harris, S Hellman, I C Henderson, D W Kinne. JB Lippincott, Philadelphia 1991; vol 2: 605–665
   Google Scholar
• Broun E R, Sridhara R, Sledge G W, et al. Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 1995; 13(8)2050–2055
   PubMed Web of Science ®Google Scholar
• Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102–110
   PubMed Web of Science ®Google Scholar
• Mulder N H, Dolsma W V, Mulder P O, et al. Long-term results of induction- and intensification chemotherapy supported with autologous bone marrow reinfusion in patients with disseminated or T4 breast cancer. Anticancer Res 1995; 15(4)1565–1568
   PubMed Web of Science ®Google Scholar
• Kalaycioglu M E, Lichtin A E, Andresen S W, et al. High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer. Am J Clin Oncol 1995; 18(6)491–494
   PubMed Web of Science ®Google Scholar
• Spitzer T R, Cirenza E, McAfee S, et al. Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue. Bone Marrow Transplant 1995; 15(4)537–542
   PubMed Web of Science ®Google Scholar
• Bezwoda W R, Seymour L, Dansey R D. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 1995; 13(10)2483–2489
   PubMed Web of Science ®Google Scholar
• Armitage J O. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1023–1030
   PubMed Web of Science ®Google Scholar
• Fisher R J, Gaynor E R, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Chabner B A. Salvage therapy for diffuse large-cell lymphoma. Blood 1990; 76(7)1267–1268
   PubMed Web of Science ®Google Scholar
• Philip T, Armitage J O, Spitzer G, et al. High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Press O W, Livingston R, Mortimer J, et al. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 1991; 9(3)423–431
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333(23)1540–1545
   PubMed Web of Science ®Google Scholar
• Salmon S E, Cassady J R. Plasma cell neoplasms. Cancer Principles and Practice of Oncology, 4th ed, V T Devita, Jr, S Hellman, A Rosenberg. JB Lippincott, Philadelphia 1993; 1984–2025
   Google Scholar
• Boccadoro M, Marmont F, Tribalto M, et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991; 9: 444–448
   PubMed Web of Science ®Google Scholar
• Barlogie B, Anderson K, Berenson J, et al. Transplants for multiple myeloma. Bone Marrow Transplant 1995; 15(1)S234–S239
   Google Scholar
• Fermand J P, Ravaud P, Chevret S C, et al. High dose therapy (HT) and autologous blood stem cell transplantation (ABSCT) versus conventional chemotherapy with HT rescue in multiple myeloma (MM): Results of a prospective randomized trial. Blood 1995; 86(10)808, (Suppl 1):(abstract 205a)
   Web of Science ®Google Scholar
• Longo D L, Young R C, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295–1306
   PubMed Web of Science ®Google Scholar
• Longo D L, Duffy D L, Young R C, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 1992; 10: 210–218
   PubMed Web of Science ®Google Scholar
• Yahalom J, Gulati S C, Toia M, et al. Accelerated hyperfractional total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 1993; 11: 1062–1070
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan A K, Linch D C, et al. The place of high dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137–1145
   PubMed Web of Science ®Google Scholar
• Nademanee A, Sniecinski I, Schmidt G, et al. high-dose therapy followed by autologous peripheral blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. J Clin Oncol 1994; 12: 2176–2186
   PubMed Web of Science ®Google Scholar
• Linch D C, Winfield D, Goldstone A H, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNL1 randomised trial. Lancet 1993; 341: 1051–1054
   PubMed Web of Science ®Google Scholar
• Carella A M. The place of high-dose therapy with autologous stem cell transplantation in primary treatment of Hodgkin's disease. Ann Oncol 1993; 4(1)15–19
   PubMedGoogle Scholar